Inhaled liposomal amikacin (Arikayce) for Mycobacterium xenopi lung infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional study gives inhaled liposomal amikacin (Arikayce) in addition to standard antimycobacterial therapy to adults who meet ATS/IDSA criteria for Mycobacterium xenopi pulmonary infection. Participants must be 18 or older and meet safety requirements for renal function, contraception, and concomitant medications; patients with cystic fibrosis, HIV, prior relapse, pregnancy, or certain drug hypersensitivities are excluded. The main outcomes will include microbiologic response (sputum culture conversion) and treatment tolerability over the prolonged treatment period typically required for nontuberculous mycobacterial infections. The trial is conducted at university hospital sites in France with clinical and safety monitoring.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years old or older
* with an highly effective or acceptable contraception
* must present ATS/IDSA 2020 criteria for nontuberculous mycobacterial pulmonary infection
* the NTM should be M. xenopi

Exclusion Criteria:

* Patients presenting any of the following criteria cannot be included:
* Known hypersensitivity to one of the molecules of the study
* Relapse of MX lung infection
* Treatment with molecules able to interfere with cytochrome P450 that cannot be replaced by another therapeutic class
* HIV 1 and 2 human immunodeficiency virus infection
* Renal failure with creatinine clearance less than 30 mL/min
* Pregnancy and breastfeeding
* Cystic fibrosis
* Contraindications to one of the antibiotic :

Contraindication to the use of ARIKAYCE®:

* Hypersensitivity to the active substance, to aminoglycosides or to any of the excipients listed in section 6.1 of the CPR.
* Hypersensitivity to soy.
* Co-administration with any other aminoglycoside, regardless of the route of administration
* Severe Renal Failure

Contraindication to the use of Clarithromycine:

Allergy to macrolides or to any of the excipients listed in section 6.1;

* Association with :

  * colchicine,
  * ergot alkaloids, including for example dihydroergotamine, ergotamine, methylergometrine, methysergide: risk of ergotism,
  * pimozide, mizolastine: risk of QT interval prolongation and cardiac rhythm disorders, in particular ventricular tachycardia, ventricular fibrillation and torsades de pointes,
  * simvastatin, due to the increased risk of myopathy, including rhabdomyolysis.
  * lomitapide,
  * alfuzosin
  * dapoxetine
  * avanafil
  * ivabradine,
  * eplerenone,
  * dronedarone,
  * Quetiapine,
  * ticagrelor,
  * cisapride,
  * astemizole,
  * terfenadine,
  * ranolazine,
  * domperidone,
* Congenital or acquired prolongation of the QT interval (see sections 4.4 and 4.5 of the CPR)
* History of QT interval prolongation or ventricular rhythm disorders, in particular torsades de pointe (see sections 4.4 and 4.5 of the CPR);
* Electrolyte imbalances (hypokalaemia or hypomagnesaemia, due to the risk of QT interval prolongation) (see sections 4.4 and 4.5 of the CPR).Clarithromycin should not be used in patients with severe hepatic insufficiency in association with renal insufficiency.

Contraindication to the use of Rifampicine:

* Hypersensitivity to rifamycins or to any of the excipients listed in section 6.1 of the CPR.
* Porphyrias.
* Association with bictegravir, cobicistat, daclatasvir, dasabuvir, delamanid, grazoprevir/elbasvir, ritonavir-boosted protease inhibitors, isavuconazole, lédipasvir, lurasidone, midostaurine, ombitasvir/paritaprévir, praziquantel, rilpivirine, sofosbuvir, velpatasvir, voriconazole, voxilaprévir, (see section 4. 5 of the CPR). In children under 6 years of age, due to the risk of malaria

Contradiction the the use of Ethambutol:

* Known hypersensitivity to ethambutol
* Optic neuritis
* This medicine is contraindicated in patients with a wheat allergy (other than coeliac disease).
* Inability to comply with the requirements of the protocol, especially substance abuse, according to the investigator.
* Limited life expectancy (e.g 3 months)
* Patients with hematologic malignancies and allogeneic haematopoietic stem cells
* Women of childbearing age and not using an effective method of contraception (Pearl Index \<1%)
* The patient is treated with molecules prolonging the QT interval that cannot be replaced by another therapeutic class.
* The patient presents a heart failure with left ventricular ejection fraction less than 30%.

Where it's running

• CHU Amiens-Picardie
  Amiens, France Recruiting

Study contacts

• Study coordinator: Claire ANDREJAK, Pr
• Email: Andrejak.Claire@chu-amiens.fr
• Phone: 03 22 08 79 98

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Electrical Impedance Tomography for Monitoring Lung Disease

  This test tries to see if a painless, noninvasive imaging method called electrical impedance tomography (EIT) can track how air is distributed in the lungs of adults with lung diseases and healthy volunteers and how those results match standard spirometry.

  Recruiting University Hospital Olomouc · Olomouc · NCT07356076

• Mosliciguat added to inhaled treprostinil for pulmonary hypertension from ILD

  This trial tests whether adding inhaled mosliciguat to your inhaled treprostinil is safe and tolerable for people with pulmonary hypertension caused by interstitial lung disease.

  Recruiting at 13 sites Phase 2 Pulmovant, Inc. · Santa Barbara, California and 12 other locations · NCT07333183

• Collecting lung sound recordings using Eko digital stethoscopes in clinic

  This project will try to teach computer programs to recognize wheeze, crackles, rhonchi, stridor, rales, and cough from stethoscope recordings in adults with suspected or diagnosed lung conditions and in people with normal lungs.

  Recruiting Eko Devices, Inc. · Mumbai, Maharashtra · NCT07270744

• Multi-omics prediction of graft problems after lung transplant

  We will test whether repeated blood and lung-fluid multi-omics tests can spot early graft dysfunction in adults after lung transplantation.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai · NCT07243964

• Recording lung sounds with Eko digital stethoscopes in clinic

  This project will test an AI that listens to lung sounds recorded with Eko digital stethoscopes to find abnormal sounds in people with or without lung disease.

  Recruiting at 2 sites Eko Devices, Inc. · Jacksonville, Florida and 1 other locations · NCT07227376

• Trop2- and EpCAM-targeted PET/CT to help distinguish non-small cell lung cancer

  This project will test whether PET/CT scans that target Trop2 and EpCAM can show protein expression in tumors of people with suspected non-small cell lung cancer.

  Recruiting RenJi Hospital · Shanghai · NCT07026110

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.